Anticipation is building for GW Pharmaceuticals (NASDAQ:GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018.
Tag Archives: Cannabinoid
The ‘Limitless Future’ of a Weed Extract That Doesn’t Get You High
CBD—a purified weed extract that won’t get you stoned—is used to treat everything from breast cancer to stress relief, epilepsy to aching joints. VICE met up with David Bonvillain, who runs the CBD company Elite Botanicals, for an inside scoop on the extract’s “limitless future.”
WEEDIQUETTE: Clinical Cannabis Treatment for Trauma
From WEEDIQUETTE’s “Chronic Trauma” episode: Krishna accompanies rapper JohnboyCOOL to learn about medicinally treating his trauma with cannabis.
Dewmar International BMC, Inc. (DEWM) Files Provisional Patent to Treat Lung Cancer with Cannabinoids
BATON ROUGE,La., July 18, 2017 /Weed Wire/ — Dewmar International BMC, Inc. (OTC PINK: DEWM) announced today that it has filed a provisional patent with the United States Patent and Trademark Office for the treatment of lung cancer with cannabinoids.
3 Things You Need to Know About Marijuana Stock Insys Therapeutics
Insys Therapeutics is one of several biotechs developing cannabinoid drugs. Unlike most of these other companies, though, Insys has already won regulatory approval for its first cannabinoid — Syndros.
Better Know a Marijuana Stock: Arena Pharmaceuticals
Unlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of their drug-development pipelines, Arena Pharmaceuticals is one of the drug developers that have some of their pipelines devoted to cannabinoid-type therapeutics or CB agonists and other portions devoted to non-cannabinoid medicines.
Better Know a Marijuana Stock: Medical Marijuana, Inc.
Medical Marijuana, Inc. holds the distinction of being the first publicly listed marijuana stock, and its diversity is rare, but is it worth investing in?
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
Hemp Pills Promise to Treat Pets
Owners of pets who suffer from arthritis and a loss of appetite are looking towards hemp pills in an effort to ease their animals’ pain.
Better Know a Marijuana Stock: Cara Therapeutics
Cara Therapeutics has been phenomenal over the past couple of years, and it’s rightfully beginning to catch the attention of marijuana stock investors.
2 Pot Stocks That Rocketed Higher by a Double-Digit Percentage
Last week, two marijuana stocks skyrocketed by a double-digit percentage. Let’s take a closer look at the possible “why” behind these moves.
This New Study Should Encourage Marijuana Stock Investors
The marijuana industry, and marijuana stock investors for that matter, have been expanding by leaps and bounds over the past two decades. One good way to keep this up is through university-based clinical studies. Studies like these really fan the flame of what might be possible with cannabis-based medicines.
Alternate Health Announces Completion of Initial Study to Treat Zika Virus Symptoms with Hemp-Derived Cannabinoids
TORONTO, Ontario, May 16, 2017 /Weed Wire/ — Alternate Health Corp. (CSE:AHG, OTC:AHGIF), a diverse healthcare company revolutionizing patient care and research in the emerging medical cannabis industry, announced today the completion of its initial study to demonstrate the effectiveness of cannabinoids in treating chronic post-Zika virus symptoms.
These 5 Marijuana Stocks Lost a Combined $193 Million in 2016
These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.
5 Drug-Developing Marijuana Stocks You Need to Know
Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.
3 Stocks to Buy if You’re Leery of Buying Marijuana Stocks
Although marijuana stocks have skyrocketed in the last couple of years, many investors have been understandably leery of jumping on board. Check out why investors might like these three stocks that don’t fit the mold of most marijuana stocks.
How to Profit From the U.S. and U.K. Marijuana ‘Research Gap’
Legal marijuana flat-Earthers, like U.S. Attorney General Jeff Sessions, have tried many methods to discredit breakthroughs in medical cannabis, but these efforts at discrediting cannabis stop at the U.S. border.
IMPACT Network Announces Clinical Research Focus on Cannabis for Women
DENVER, March 15, 2017 /Weed Wire/ — IMPACT Network, a nonprofit dedicated to Improving Marijuana Policy and Accelerating Cannabinoid Therapeutics, announced their new focus on cannabis for women’s health, as well as several new executive team appointments that will support Founder and Executive Director, Dr. Michele Ross, and newly promoted Deputy Executive Director Susan Parker.
World of Cannabis Summit: Evoxe
President of Evoxe Laboratories, Michael Katz, presents this emerging brand’s business model that lead to its current success.
GW Pharmaceuticals Takes A Step Toward Diversifying
The company announced Tuesday positive top-line results from a mid-stage placebo-controlled study of a proprietary combination of tetrahydrocannabinol, or THC, and cannabidiol, or CBD, for treating glioblastoma multiforme, or GBM.
Federal Overreach: Round 1 Hoban Law Group Files Ninth Circuit Petition to Challenge Recent DEA Classification of “Marihuana Extracts”
DENVER, Jan. 16, 2016 /Weed Wire/ — Hoban Law Group has filed a petition in San Francisco’s United States Court of Appeals for the Ninth Circuit to challenge what appears to be the DEA’s attempt to control an otherwise lawful substance.
Cannabis Science’s Report of New Facility Makes Market Happy
As Cannabis Science Inc (OTCMKTS:CBIS) goes forward into 2017 with its stock, the company recently announced about its new drug facility in Nevada.
Vitality Biopharma: A Seriously Undervalued Cannabis Stock
While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.
International Cannabis Corporation Announces Incorporation of Additional Land to Increase Production Capacity
VANCOUVER, British Columbia, Dec. 20, 2016 /Weed Wire/ — ICC International Cannabis Corporation (“ICC” or the “Company”) (TSXV: ICC) has entered into an agreement to lease approximately 9 hectares of additional land adjacent to the Company’s existing property used for the production of cannabinoid extracts and by-products for medicinal use and industrial hemp.
Marijuana Investing in 2017: 5 Numbers Everyone Should Know
If you’re considering investing in marijuana stocks in the new year, here are five numbers you should know before taking the plunge.
Journey into the Endocannabinoid System
From children with seizures to athletes with joint pain, people are using cannabis to cope effectively. This one herb and its variety of therapeutic compounds seem to affect every aspect of our bodies and minds. How is this possible?
UK Media Reports: NHS Testing a Cannabis Vaporizer
MediPen, a cannabis vaporizer, is being tested by the United Kingdom’s National Health Service, according to an Aug. 15, 2016, article in The Independent. It’s the first time a cannabis-based product has been tested by the NHS.
Dixie Brands, Inc. Launches Aceso Daily Powder, the First-Ever Cannabinoid Drink Mix
DENVER, May 11, 2016 /Weed Wire/ — Dixie Brands Inc. (Dixie), a leader in emerging cannabinoid extraction and wellness platforms, announces the expansion of its Aceso line of products with the launch of a delicious, dissolvable effervescent drink mix featuring hemp-derived cannabinoids, boosted with all-natural vitamins and terpenes.
New Technique Could More Accurately Measure Cannabinoid Dosage in Marijuana Munchies
SAN DIEGO, March 15, 2016 /Weed Wire/ — As more states decriminalize recreational use of marijuana and expand its medical applications, concern is growing about inconsistent and inaccurate dosage information listed on many products, including brownies and other edibles.
Lexaria Proposes to Change Name to Lexaria Bioscience Corp
KELOWNA, British Columbia, Feb. 19, 2016 /Weed Wire/ — Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) announces that at the Annual General Meeting expected to be held March 23, 2016, the Company proposes to change its name to Lexaria Bioscience Corp.
Cannabis Science Targets Successful Autism Treatments and Brings Family Autism Advocate Mieko Hester-Perez on Its Scientific Advisory Board
COLORADO SPRINGS, Colo., Feb. 8, 2016/ Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced its next critical ailment target is autism and brings Mieko Hester-Perez on its Scientific Advisory Board to lead this charge.
Livestreamed Seniors & Cannabis Conference Hosted By Impact Network January 9th
DENVER, Jan. 8, 2015 /Weed Wire/ — The second free IMPACT event on Seniors and Cannabis will be held on Saturday, January 9th, from noon to 5 pm at Green Labs in Denver’s RiNo district.
Revolution Cannabis Analytics Launches First-of-its-Kind Statewide Study
DOWNERS GROVE, Ill., Dec. 7, 2015 /WeedWire/ — Revolution Cannabis Analytics will document the choices, attitudes, and experience of medical cannabis patients in Illinois in a first-of-its-kind study.
Endocannabinoid Deficiency Foundation Changing Name to Impact Network
The Endocannabinoid Deficiency Foundation will officially become the Impact Network on November 1, 2015.
Zynerba: The Need for Speculative Fortitude
Zynerba presented the status of its research program at BIO Investor Forum. This is a 14-year-old annual biotech gathering, with roughly 600 attendees from 21 countries, and the presentation, in San Francisco, looked likely to be a big event in this company’s development.
Lexaria Releases Press Kit to the Media
KELOWNA, B.C., July 7, 2015 /Weed Wire/ – Lexaria Corp. (CSE: LXX) (OTCQB: LXRP), a food sciences company focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technology, today announced the release of its official press kit providing media partners with detailed information about the company and its technologies, as well as high resolution images and other assets to assist with content creation.
Seven in DC Hospitalized as Synthetic Marijuana Overdose Numbers Spike
About seven residents at a District of Columbia homeless shelter were hospitalized last week after overdosing on a synthetic marijuana product. Synthetics are making more people sick.
Insys Investor Case Study – When Bad News is OK
Last Wednesday, two pain specialists that were top subscribers of Insys Therapeutics’ (NASDAQ: INSY) leading prescription therapy Subsys were arrested, as part of a year-long operation by the DEA.
Marijuana 101: Chemical Compounds Beyond Abbreviations
As a newcomer to the legal cannabis space, the alphabet soup of chemical chemotypes, or distinct chemical compounds, can be overwhelming. These abbreviations should not be dismissed because they indicate the chemical composition of cannabis plants.
FDA OKs Cannabis-Based Ovarian Cancer Treatment
The Federal Drug Administration is willing to support continued research into a treatment option that is based on Dronabinol, a cannabinoid, which is one of the many non-THC derivatives of the cannabis plant.
The Handheld Device That Will Revolutionize Cannabis Testing and Optimization, Daniel Yazbeck, CEO of CDx
MyDx is a handheld device straight out of a Star Trek episode. Simply place a small amount of cannabis into it’s sensor and watch as your smart phone is illuminated with information about the plant.
Cannasafe Analytics
CannaSafe Analytics (CSA LABS) is the only national ISO17025:2005 accredited cannabis testing laboratory. CannaSafe’s accredited scope includes full cannabinoid and terpenoid profiling, microbiological, heavy metals, pesticide contamination, plant growth regulars and residual solvents.
Cannabis Therapy Corp. Prepares for Colorado Cannabis Summit
Cannabinoid research company, Cannabis Therapy Corp., is expected to present at an upcoming cannabis summit in Denver.
Avoid K2 Counterfeit Cannabis
Some Americans risk their lives with K2, a dangerous chemical alternative, because using marijuana leaves evidence in the bloodstream.
Look Out Big Pharma: GW’s in Town
GW Pharma utilizies CBD technology in order to develop a new breakthrough treatment for pediatric epilepsy.